4.7 Article

Clinical phenotypes of chronic obstructive pulmonary disease and asthma: Recent advances

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 131, 期 3, 页码 627-634

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2013.01.010

关键词

Biomarker; biopsy; cluster analysis

资金

  1. Forest Laboratories
  2. GlaxoSmithKline
  3. Merck/Schering-Plough
  4. Novartis
  5. Dey
  6. Genentech
  7. Boehringer Ingelheim
  8. National Institutes of Health

向作者/读者索取更多资源

Asthma and chronic obstructive pulmonary disease (COPD) are prevalent obstructive lung diseases, both of which are characterized by airflow limitation. Although both represent distinct pathogenic entities, there can be significant clinical and physiologic overlap between the 2 disorders, creating potential management difficulties for clinicians. Although practice guidelines for both conditions outline diagnostic and management strategies, asthma and COPD are highly heterogeneous, and the symptoms of many patients remain poorly controlled despite adherence to current guidelines. Recent advances in phenotyping studies have elucidated heterogeneity in these airway diseases and might represent the best opportunity to enhance diagnosis, predict outcomes, and personalize treatments in patients with asthma and those with COPD. This review will focus on recent advances in describing phenotypic heterogeneity in asthma and COPD, including the evaluation of multiple clinical variables, molecular biomarkers, physiologic and radiologic data, and factors associated with disease progression and frequent exacerbations. (J Allergy Clin Immunol 2013;131:627-34.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据